携带BRCA2突变的转移性透明细胞子宫内膜腺癌对聚（ADP核糖）聚合酶（PARP）抑制剂奥拉帕尼的完全缓解
Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
作者信息
Anzellini Dimitri, Arcangeli Gianluca, Del Bianco Sergio
机构信息
Precision Oncology Department, Sanatrix Clinic, Rome, Italy.
出版信息
Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080. eCollection 2022 Jan-Feb.
BACKGROUND
Cancer of the endometrium is the most common gynecologic malignancy in developed countries and the second most common in developing countries. Endometrioid tumors tend to have a favorable prognosis and typically present at an early stage with abnormal uterine bleeding. Clear cell carcinoma as well as serous endometrial carcinoma are associated with a poorer prognosis. Patients with metastatic endometrial cancer are treated with systemic therapy either following surgery or as primary therapy. As far as second-line chemotherapy is concerned, there are no general agreements on the chemotherapy to be used. Furthermore, to the best of knowledge, there are no studies on the use of poly (ADP ribose) polymerase (PARP) inhibitors in endometrial cancer even in BRCA mutated tumors.
CASE REPORT
We here present the case report of an 81-year-old woman with a mutated BRCA2 metastatic clear cell endometrial adenocarcinoma that showed an excellent clinical and radiological response to the PARP inhibitor olaparib.
CONCLUSION
Olaparib could be successfully used in this patient setting.
背景
子宫内膜癌是发达国家最常见的妇科恶性肿瘤，在发展中国家是第二常见的。子宫内膜样肿瘤往往预后良好，通常在早期以子宫异常出血为表现。透明细胞癌以及浆液性子宫内膜癌预后较差。转移性子宫内膜癌患者在手术后或作为初始治疗接受全身治疗。就二线化疗而言，对于使用何种化疗方案尚无普遍共识。此外，据了解，即使在BRCA突变的肿瘤中，也没有关于聚（ADP核糖）聚合酶（PARP）抑制剂用于子宫内膜癌的研究。
病例报告
我们在此报告一例81岁女性，患有BRCA2突变的转移性透明细胞子宫内膜腺癌，对PARP抑制剂奥拉帕尼表现出出色的临床和影像学反应。
结论
奥拉帕尼在该患者情况下可成功使用。
Zotero 插件